The trial, involving approximately 45 subjects, is expected to be completed by the end of the first quarter of 2007. The company said it hopes to initiate phase II studies with TG100801 in mid-2007.
TG100801, applied daily in eye drop form, is designed to suppress disease-related edema, angiogenesis and inflammation. Currently approved therapies for AMD require repeated injection into the eye and typically act on only VEGF-mediated retinal leakage.
The company believes that TG100801 may offer equal or superior efficacy to injectable agents, while offering patients the greater convenience and potential safety advantages of non-invasive delivery.